{"id":44550,"date":"2016-01-11T00:00:00","date_gmt":"2016-01-11T05:00:00","guid":{"rendered":"https:\/\/asweetlife.org\/fda-approves-animas-vibe-and-cgm-for-children\/"},"modified":"2017-02-21T08:25:55","modified_gmt":"2017-02-21T13:25:55","slug":"fda-approves-animas-vibe-and-cgm-for-children","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=44550","title":{"rendered":"FDA Approves Animas Vibe and CGM for Children"},"content":{"rendered":"

The U.S. FDA has approved Animas Vibe Insulin Pump and Continuous Glucose Monitoring (CGM) System<\/a> for management of diabetes in children and adolescents, ages 2 to 17.<\/p>\n

The Animas Vibe System was the first integrated system with Dexcom G4 PLATINUM CGM technology and is the only such system available in the U.S. for pediatric patients as young as age 2.\u00a0The Animas Vibe allows patients and their caregivers to view glucose data and administer insulin right from the pump, making it easy to fine tune insulin delivery to help manage their diabetes. \u00a0<\/span><\/p>\n

The value of insulin pump therapy has been demonstrated in numerous clinical studies, showing significant improvement in blood glucose control when compared to multiple daily injections. Furthermore, studies have shown that patients who used insulin pump therapy in combination with CGM obtained lower HbA1c levels, relative to patients who used multiple daily injections and self- monitoring of blood glucose.This greater insight into blood glucose trends helps children with Type 1 diabetes and their parents to make more informed decisions about their insulin needs.<\/span><\/p>\n

In addition to the inclusion of CGM, the Animas\u00ae Vibe\u00ae System offers a unique combination of features including:<\/span><\/p>\n